radiation

MDPI

Editorial

Radiation: A New Multi-Disciplinary Open Access Journal for Advances in Radiation Technology

Gabriele Multhoff

Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany; gabriele.multhoff@tum.de

Received: 18 March 2021; Accepted: 18 March 2021; Published: 19 March 2021

Radiation is a perpetual part of our daily life. Over the years, we have learned to harness its power and refocus it for applications across multiple fields such as medicine, biology, engineering, biophysics, and physics. Given the broad nature of scientific advances in radiation technology, the newly launched journal *Radiation* [1] aims to bring these fields together and welcomes the submission of high-quality multi-disciplinary research articles, reviews, and communications. We would like *Radiation* to become a platform for sharing new breakthrough research and sparking ideas and collaborations amongst researchers with diverse backgrounds.

To achieve our aim, the scope of *Radiation* will cover advances in diagnostic [2–4] or therapeutic use of radiation either alone or in combination with other treatment modalities [5], mechanistic and fundamental studies in radiation biology, development of radiation detectors and equipment for biophysical/biomedical imaging and radiation dosimetry, environmental radiation and impact on health, and novel techniques for radiation protection. The common thread to tie in these areas will be the impact of these advances on health and quality of life. We are interested in showcasing how developments in one field can be applied across others; for example, how technical advances in radiation sources and technologies can lead to improved diagnostic or imaging techniques and therapeutic strategies in the fields of oncology, radiology, or biomedicine.

Radiation will be published on a quarterly basis by MDPI and with the support of our Editorial Board Members, we will ensure a rigorous yet fast peer-review process to ensure rapid and scientifically accurate dissemination of research. We would like to thank all the experts from across multiple fields who have kindly agreed to serve on the Editorial Board and invite all researchers involved in advancing radiation technology to submit their new discoveries and help us develop *Radiation* into a top-rated multidisciplinary journal.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Radiation. Available online: https://www.mdpi.com/journal/radiation (accessed on 10 May 2020).
2. Stangl, S.; Tontcheva, N.; Sievert, W.; Shevtsov, M.; Niu, M.; Schmid, T.E.; Pigorsch, S.; Combs, S.E.; Haller, B.; Balermpas, P.; et al. Heat shock protein 70 expression and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck (SCCHN) after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology (DKTK-ROG). *Int. J. Can.* **2018**, *142*, 1911–1925.
3. Tzoumas, S.; Nunes, A.; Olefir, I.; Stangl, S.; Symvoulidis, P.; Glasl, S.; Bayer, C.; Multhoff, G.; Ntziachristos, V. Eigenspectra optoacoustic tomography achieves quantitative blood oxygenation imaging deep in tissues. *Nat. Commun.* **2016**, *7*. [CrossRef] [PubMed]
4. Shevtsov, M.; Stangl, S.; Nikolaev, B.; Yakovleva, L.; Marchenko, Y.; Tagaeva, R.; Sievert, W.; Pitkin, E.; Mazur, A.; Tolstoy, P.; et al. Granzyme B functionalized nanoparticles targeting membrane Hsp70-positive tumors for multimodal cancer theranostics. *Small* **2019**, *15*, e1900205. [CrossRef] [PubMed]

5. Multhoff, G.; Seier, S.; Stangl, S.; Sievert, W.; Shevtsov, M.; Werner, C.; Pockley, A.G.; Blankenstein, C.; Hildebrandt, M.; Offner, R.; et al. Targeted NK cell based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: A randomized phase II clinical trial. *Clin. Can. Res.* **2020**, *26*, 5368–5379. [CrossRef] [PubMed]

Short Biography of Author

Gabriele Multhoff: Prof. Dr. Gabriele Multhoff is heading the Research group "Radiation Immuno-Oncology" at the Central Institute for Translational Cancer Research, Klinikum rechts der Isar, TU München (TranslaTUM). For more than 15 years, Prof. Multhoff has had a research interest in the development of innovative immunotherapies based on NK cells, antibodies, and targeting nanoparticles in combination with radiation therapy. Prof. Multhoff's research group aims to identify tumor-specific biomarkers for multimodal tumor imaging and theranostic purposes and studies radiation-induced mechanisms in normoxic and hypoxic tumor cells.